



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70	A1	(11) International Publication Number: WO 00/28997 (43) International Publication Date: 25 May 2000 (25.05.00)
<p>(21) International Application Number: PCT/AU99/01004</p> <p>(22) International Filing Date: 12 November 1999 (12.11.99)</p> <p>(30) Priority Data: 60/108,254 12 November 1998 (12.11.98) US</p> <p>(71) Applicant (for all designated States except US): ANALYTICA LTD [AU/AU]; 194-198 St Kilda Road, St Kilda, Victoria 3182 (AU).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): TSENG, Albert, Peng, Sheng [AU/AU]; 6 Wyvern Street, Epping, New South Wales 2121 (AU), BROADY, Kevin, William [AU/AU]; 45 Yaralla Crescent, Thornleigh, New South Wales 2120 (AU).</p> <p>(74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER</p> <p>(57) Abstract</p> <p>The present invention relates generally to a method of treating disease conditions by the administration of an inhibitor of phospholipase activity. More particularly, the present invention contemplates a method for facilitating apoptosis of cancer cells or otherwise reducing or preventing growth of cancer cells by inhibiting phospholipase activity. Even more particularly, the present invention contemplates the use of inhibitors of phospholipase A₂ enzymes in the treatment and prophylaxis of cancer. The present invention further provides biological compositions comprising an inhibitor of phospholipase A₂ alone or in combination with other agents in the treatment of cancer.</p>		